Naoki Nakamura1, Sadamoto Zenda2, Makoto Tahara3, Susumu Okano3, Ryuichi Hayashi4, Hidehiro Hojo2, Kenji Hotta2, Satoe Kito2, Atsushi Motegi2, Satoko Arahira5, Hidenobu Tachibana2, Tetsuo Akimoto2. 1. Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: naoknaka@east.ncc.go.jp. 2. Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan. 3. Division of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Japan. 4. Division of Head and Neck Oncology, National Cancer Center Hospital East, Kashiwa, Japan. 5. Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan; Department of Radiation Oncology, Kanto Rosai Hospital, Kawasaki, Japan.
Abstract
PURPOSE: To clarify the efficacy and feasibility of proton beam therapy (PBT) for olfactory neuroblastoma (ONB). METHODS AND MATERIALS: We retrospectively reviewed 42 consecutive patients who received PBT with curative intent for ONB at National Cancer Center Hospital East from November 1999 to March 2012. RESULTS: Five patients (12%) had Kadish A disease, nine (21%) had Kadish B, and twenty-eight (67%) had Kadish C. All patients except one received a total dose of 65Gy (relative biological effectiveness: RBE) in 26 fractions. Twenty-four patients (57%) received induction and/or concurrent chemotherapy. The median follow-up for all eligible patients was 69months (7-186). The 5-year overall survival (OS) and progression-free survival (PFS) rates were 100% and 80% for Kadish A, 86 and 65% for Kadish B, and 76% and 39% for Kadish C, respectively. The sites of the first progression were local in six patients (30%), regional in eight (40%), distant in two (10%), local and regional in two (10%), and local and distant in two (10%). Late adverse events of grade 3-4 were seen in six patients (ipsilateral visual impairment, 3; bilateral visual impairment, 1; liquorrhea, 1; cataract, 1). CONCLUSION: PBT was a safe and effective modality for ONB.
PURPOSE: To clarify the efficacy and feasibility of proton beam therapy (PBT) for olfactory neuroblastoma (ONB). METHODS AND MATERIALS: We retrospectively reviewed 42 consecutive patients who received PBT with curative intent for ONB at National Cancer Center Hospital East from November 1999 to March 2012. RESULTS: Five patients (12%) had Kadish A disease, nine (21%) had Kadish B, and twenty-eight (67%) had Kadish C. All patients except one received a total dose of 65Gy (relative biological effectiveness: RBE) in 26 fractions. Twenty-four patients (57%) received induction and/or concurrent chemotherapy. The median follow-up for all eligible patients was 69months (7-186). The 5-year overall survival (OS) and progression-free survival (PFS) rates were 100% and 80% for Kadish A, 86 and 65% for Kadish B, and 76% and 39% for Kadish C, respectively. The sites of the first progression were local in six patients (30%), regional in eight (40%), distant in two (10%), local and regional in two (10%), and local and distant in two (10%). Late adverse events of grade 3-4 were seen in six patients (ipsilateral visual impairment, 3; bilateral visual impairment, 1; liquorrhea, 1; cataract, 1). CONCLUSION: PBT was a safe and effective modality for ONB.
Authors: Matt Lechner; Yoko Takahashi; Mario Turri-Zanoni; Jacklyn Liu; Nicholas Counsell; Mario Hermsen; Raman Preet Kaur; Tianna Zhao; Murugappan Ramanathan; Volker H Schartinger; Oscar Emanuel; Sam Helman; Jordan Varghese; Jozsef Dudas; Herbert Riechelmann; Susanne Sprung; Johannes Haybaeck; David Howard; Nils Wolfgang Engel; Sarah Stewart; Laura Brooks; Jessica C Pickles; Thomas S Jacques; Tim R Fenton; Luke Williams; Francis M Vaz; Paul O'Flynn; Paul Stimpson; Simon Wang; S Alam Hannan; Samit Unadkat; Jonathan Hughes; Raghav Dwivedi; Cillian T Forde; Premjit Randhawa; Simon Gane; Jonathan Joseph; Peter J Andrews; Gary Royle; Alessandro Franchi; Roberta Maragliano; Simonetta Battocchio; Helen Bewicke-Copley; Christodoulos Pipinikas; Amy Webster; Chrissie Thirlwell; Debbie Ho; Andrew Teschendorff; Tianyu Zhu; Christopher D Steele; Nischalan Pillay; Bart Vanhaesebroeck; Ahmed Mohyeldin; Juan Fernandez-Miranda; Ki Wan Park; Quynh-Thu Le; Robert B West; Rami Saade; R Peter Manes; Sacit Bulent Omay; Eugenia M Vining; Benjamin L Judson; Wendell G Yarbrough; Maddalena Sansovini; Nicolini Silvia; Ilaria Grassi; Alberto Bongiovanni; David Capper; Ulrich Schüller; Selvam Thavaraj; Ann Sandison; Pavol Surda; Claire Hopkins; Marco Ferrari; Davide Mattavelli; Vittorio Rampinelli; Fabio Facchetti; Piero Nicolai; Paolo Bossi; Oswaldo A Henriquez; Kelly Magliocca; C Arturo Solares; Sarah K Wise; Jose L Llorente; Zara M Patel; Jayakar V Nayak; Peter H Hwang; Peter D Lacy; Robbie Woods; James P O'Neill; Amrita Jay; Dawn Carnell; Martin D Forster; Masaru Ishii; Nyall R London; Diana M Bell; Gary L Gallia; Paolo Castelnuovo; Stefano Severi; Valerie J Lund; Ehab Y Hanna Journal: Eur J Cancer Date: 2021-12-31 Impact factor: 10.002
Authors: Ming Fan; Jung Julie Kang; Anna Lee; Dan Fan; Huili Wang; Sarin Kitpanit; Pamela Fox; Kevin Sine; Dennis Mah; Sean M McBride; Chiaojung Jillian Tsai; Nadeem Riaz; Lara A Dunn; Eric J Sherman; Loren Michel; Bhuvanesh Singh; Ian Ganly; Richard J Wong; Jay O Boyle; Marc A Cohen; Nancy Y Lee Journal: Cancer Date: 2020-02-25 Impact factor: 6.860
Authors: Jakob Liermann; Mustafa Syed; Thomas Held; Denise Bernhardt; Peter Plinkert; Christine Jungk; Andreas Unterberg; Stefan Rieken; Jürgen Debus; Klaus Herfarth; Sebastian Adeberg Journal: Cancers (Basel) Date: 2018-11-20 Impact factor: 6.639
Authors: Satoshi Kiyofuji; Vijay Agarwal; Joshua D Hughes; Robert L Foote; Jeffrey R Janus; Eric J Moore; Caterina Giannini; Michael J Link; Jamie J Van Gompel Journal: J Neurol Surg B Skull Base Date: 2020-03-25